Stay updated on CT-P13 SC vs IV in RA: Efficacy, PK, Safety Clinical Trial
Sign up to get notified when there's something new on the CT-P13 SC vs IV in RA: Efficacy, PK, Safety Clinical Trial page.

Latest updates to the CT-P13 SC vs IV in RA: Efficacy, PK, Safety Clinical Trial page
- Check6 days agoChange DetectedAdded related topic links for Rheumatoid arthritis and MedlinePlus Genetics on the Study Details page. These links provide quick access to additional information.SummaryDifference0.2%

- Check13 days agoChange DetectedMinor administrative updates were applied: Revision: v3.4.2 was added, and references to Rheumatoid arthritis and related topics (MedlinePlus Genetics) along with Revision: v3.4.1 were removed; core study information remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check20 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 on the page footer; this is a deployment/version update and does not affect study content or results.SummaryDifference0.1%

- Check27 days agoChange DetectedAdded Show glossary and updated footer metadata to Revision: v3.4.0, including 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'. Removed older footer items: 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.SummaryDifference0.2%

- Check35 days agoChange DetectedDeleted the page's related topics: Rheumatoid arthritis and MedlinePlus Genetics. This reduces metadata context but does not change the study's details or eligibility information.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision banner updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to CT-P13 SC vs IV in RA: Efficacy, PK, Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CT-P13 SC vs IV in RA: Efficacy, PK, Safety Clinical Trial page.